Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Arcutis' ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rated “Moderate Buy” by Wall Street Brokerages

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Masaru Matsuda Sells 3,674 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Bamco Inc. NY Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT

5 Biotech Stocks Worth Adding to Your Portfolio Now

382,682 Shares in Arcutis Biotherapeutics, Inc. $ARQT Bought by Deutsche Bank AG

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates

Arcutis Biotherapeutics Q2 Earnings Call Highlights

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update